rm and germs, it must do so without hurting the friendly bacteria in a healthy vagina, like the lactobacilli, he explains. Also, it mustnt smell bad or taste bad or stain the sheets. And most importantly, it mustnt irritate sensitive vaginal tissues. BufferGel has met those standards both in animal trials and in extensive clinical safety trials, according to Cone.
For the new contraceptive efficacy trial, researchers at 10 sites in the United States are enrolling 1,000 women. Participants must be in a sexually active and monogamous relationship and at low risk for infection by sexually transmitted diseases. They must agree not to use other forms of contraception beyond that supplied by the study, and be willing to risk getting pregnant. Study participants will use a diaphragm with either BufferGel or a conventional spermicide.
In this trial, we want to achieve the highest possible level of protection, says Thomas Moench, medical director for ReProtect LLC. Were including a diaphragm because it places a discrete physical barrier over the cervix, significantly enhancing the protective actions of contraceptive microbicides.
Moench, formerly an assistant professor of infectious diseases at the Johns Hopkins Medical Institutions, originally created BufferGel with Cone. Hopkins and ReProtect LLC are developing BufferGel through a cooperative research agreement.
Researchers are also currently planning a larger trial to test BufferGels ability to block transmission of HIV and genital herpes. The trial is scheduled to take place through NIHs HIV Prevention Trials Network next year.
Page: 1 2 Related biology news :1
Contact: Michael Purdy
Johns Hopkins University
. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies2
. UT Southwestern researchers discovery may lead to gene targets for new form of contraceptive3
. Oral contraceptives increase C-reactive protein, an infIammatory biomarker4
. The contraceptive plague5
. Newly found estrogen role in males might lead to contraceptive for men6
. New study shows oral contraceptive may be effective in treating severe form of premenstrual syndrome7
. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin8
. Study suggests newer oral contraceptives may be less harmful for women smokers9
. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research10
. Images reveal how rotavirus - leading cause of diarrhea - enters cells11
. Proteomic research centers target bioterrorism agents, infectious diseases